We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 2,930

The pitfalls of employee-created IP
  • Spruson & Ferguson
  • China
  • October 13 2016

In recent years, increasing numbers of European companies have moved research and development (R&D) activities to China. For some, their China R&D is

Data protection: defining innovative drug in Canada
  • Gowling WLG
  • Canada
  • April 22 2013

Canada amended its Data Protection Regulations in 2006 to provide protection for innovative drugs in a second attempt to implement Canada's 1994

Universities abroad experiment with no-fee licensing to drive biotech partnerships
  • Shook Hardy & Bacon LLP
  • Canada, European Union, United Kingdom, USA, Australia
  • May 16 2013

Universities in Australia, Canada, Europe, and the United Kingdom have reportedly embraced a 2010 Glasgow University initiative under which companies

Ninth Circuit to consider impact of trial court error in admitting expert testimony
  • Shook Hardy & Bacon LLP
  • USA
  • April 4 2013

In related cases that could have implications for intellectual property, consumer safety and complex litigation where resolution of the dispute

Re-branding of parallel imported medicines ruled unlawful - speciality European Pharma v Doncaster pharmaceuticals
  • D Young & Co
  • European Union, United Kingdom
  • March 3 2014

The parallel import of pharmaceuticals into the UK from other European Union (EU) countries has been common practice for over 30 years. Indeed, the

A Swiss MA is the "first authorisation" for the purpose of an SPC
  • Taylor Wessing
  • European Union, Switzerland
  • April 29 2014

Further to a request for a preliminary ruling from the High Court of Justice (England and Wales), in the proceeding AstraZeneca AB v Comptroller

Ukraine adopts compulsory licensing of pharmaceutical patents
  • Asters
  • Ukraine
  • March 25 2013

Ukraine is harmonising its national legislation with EU requirements on the compulsory licensing of pharmaceutical patents, which will allow

Nagoya Protocol enters into force on 12 October 2014
  • Henry Hughes IP
  • Australia, Global, New Zealand
  • August 7 2014

The Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilisation, a supplementary

Key regulatory issues for strategic life sciences partnerships in China
  • Morrison & Foerster LLP
  • China
  • January 16 2013

In the first installment of this series of three articles, we presented an overview of the drivers behind the recent trend toward entering into

Telehealth and health IT Policy: considerations for stakeholders
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • September 4 2014

In recent months, as the conversation about reforming the health care system has shifted to achieving greater delivery system efficiencies, cost